drugset / Trial / NCT05487781
Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin
RandomizedSingle-groupDouble-blindTreatment
Summary
Evaluate the biological safety and pharmacokinetics of tyrphostin AG-17 present in the solid oral formulations of the fixed-dose combination, in three different concentrations of the compound tyrphostin AG-17 contained 10 mg, 3.3 mg and 1 mg, respectively, with 700 mg of L-Carnitine tartrate each presentation, in a single dose in healthy research subjects of Mexican nationality.
Timeline
- Start
- 2022-05-24
- Primary completion
- 2022-06-28
- Completion
- 2022-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirfostina | Unknown | 1 mg | Oral |
| Subject | Tirfostina | Unknown | 3.3 mg | Oral |
| Subject | Tirfostina | Unknown | 10 mg | Oral |
| Background | L-carnitine | Other / unclassified | 700 mg | Oral |
Indications
No indication recorded.